Artiva Biotherapeutics, Inc.
ARTVArtiva Biotherapeutics is a clinical-stage biotechnology company developing allogeneic, natural killer (NK) cell-based therapies for autoimmune diseases and cancers.
Earnings
Next report
Date not yet announcedValuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Artiva Biotherapeutics is a clinical-stage biotechnology company developing allogeneic, natural killer (NK) cell-based therapies for autoimmune diseases and cancers. The company utilizes a proprietary 'off-the-shelf' manufacturing platform to produce cryopreserved, non-genetically modified NK cells derived from donor cord blood. Its core value proposition lies in providing scalable, outpatient-compatible cell therapies that aim to avoid the safety and logistical limitations associated with traditional autologous CAR-T treatments.
A first-mover in allogeneic NK cell therapy for autoimmune diseases with a focus on outpatient community-based administration and low-cost manufacturing.
FAQ
- What is Artiva Biotherapeutics, Inc.'s market cap?
- Artiva Biotherapeutics, Inc. (ARTV) has a market capitalization of $551.0M and trades on XNAS.
- Who are Artiva Biotherapeutics, Inc.'s competitors?
- Artiva Biotherapeutics, Inc.'s key competitors include Nkarta, Inc., Kyverna Therapeutics, Inc., Cabaletta Bio, Inc., and others. These companies compete in similar markets and product categories.
- Who does Artiva Biotherapeutics, Inc. partner with?
- Artiva Biotherapeutics, Inc.'s notable partners include GC Cell, Integral Rheumatology & Immunology Specialists, Incyte Corporation, and others.
- Where is Artiva Biotherapeutics, Inc. headquartered?
- Artiva Biotherapeutics, Inc. is headquartered in United States of America. It has been publicly traded since 2024.